Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products. The equity injection of SEK 60 million will be used to advance the development of Ascelia Pharma’s drug candidates – Mangoral® and Oncoral.

“I am highly satisfied with the support from both current and new shareholders and their confidence in Ascelia Pharma and our promising drug candidates. The funding will enable us to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma